UM-UC-10Homo sapiens (Human)Cancer cell line
Also known as: University of Michigan-Urothelial Carcinoma-10, UMUC10
🤖 AI SummaryBased on 5 publications
Quick Overview
Human bladder cancer cell line with known genetic alterations and tumorigenic potential.
Detailed Summary
UM-UC-10 is a human bladder cancer cell line derived from transitional cell carcinoma. It exhibits specific genetic alterations, including mutations in the TERT promoter and TP53 gene, which are common in urothelial cancers. The cell line has been used in studies investigating tumor progression, genetic mutations, and therapeutic responses. It is also part of panels for molecular profiling and drug sensitivity testing. UM-UC-10 has been characterized for its ability to form tumors in vivo, making it a valuable model for preclinical research. Its genetic profile and behavior in experimental models provide insights into bladder cancer biology and potential treatment strategies.
Research Applications
Genetic mutation analysisTumor progression studiesDrug sensitivity testingMolecular profilingIn vivo tumorigenicity
Key Characteristics
TERT promoter mutationsTP53 mutationsTumorigenic in vivoPart of molecular profiling panels
Generated on 6/19/2025
Basic Information
| Database ID | CVCL_2744 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Urinary bladder[UBERON:UBERON_0001255] |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Male |
Disease Information
| Disease | Bladder carcinoma |
|---|---|
| Lineage | Bladder/Urinary Tract |
| Subtype | Bladder Urothelial Carcinoma |
| OncoTree Code | BLCA |
DepMap Information
| Source Type | Sigma-Aldrich |
|---|---|
| Source ID | ACH-001412_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Glu285Lys (c.853G>A) | Unspecified | Temperature-sensitive | PubMed=23851445, PubMed=17260012 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X,Y
CSF1PO
11,12,14
D13S317
11,12
D16S539
9,11
D18S51
13
D21S11
30.2,33.2
D3S1358
15,17
D5S818
12
D7S820
12,13
D8S1179
13
FGA
25
Penta D
12
Penta E
12,17
TH01
6,7
TPOX
8
vWA
17,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Bladder Cancer 4:169-183(2018).
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Chanock S.J., Valencia A., Real F.X.
BMC Genomics 16:403.1-403.16(2015).
Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.
Eur. Urol. 65:360-366(2014).
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Kwiatkowski D.J.
J. Pathol. 230:17-27(2013).
The use of short tandem repeat profiling to characterize human bladder cancer cell lines.
Chiong E., Dadbin A., Harris L.D., Sabichi A.L., Grossman H.B.
J. Urol. 181:2737-2748(2009).
Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.
Czerniak B.
J. Natl. Cancer Inst. 100:1401-1411(2008).